Description
Introduction:
The KRIBIOLISA ELISA kits are used for assessing the specific biomarker in samples analytes which may be serum and cell culture supernatant as validated with the kit. The kit employs a competitive ligand binding assay (CLBA) ELISA technique which engages the competition between Liraglutide and HRP conjugated Liraglutide to bind to the immobilized Anti-GLP1. Liraglutide (NN2211) is a derivative of a human incretin (metabolic hormone), glucagon-like peptide-1 (GLP-1)that is used as a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as doesthe endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing a separate strength in the U.S. and E.U. under the brand name Saxenda as a treatment for adults who are obese or overweight with at least one weight-related comorbid condition. A neutralizing antibody (NAb) is an antibody that is responsible for defending cells from pathogens and are produced naturally by the body as part of its immune response. Their production is triggered by both infections and vaccinations against infections. In an immunogenetic context it will bind to a drug and neutralize its therapeutic effect.
Intended Use:
The KRIBIOLISA Neutralizing Antibodies to Liraglutide (Victoza) ELISA kit is used as an analytical tool for the qualitative detection of neutralizing antibodies against Liraglutide in serum or plasma.
Principle:
The method employs sandwich ELISA technique with competition between unbound Liraglutide and HRP conjugated Liraglutide to bind to the immobilized Anti-GLP1. Samples and controls are pipetted in a blank microtitre plate and incubated with neutralizing antibody to Liraglutide (NAb) and Liraglutide. This complex of bound and unbound Liraglutide is then incubated in the immobilized Anti-GLP1 microplate. HRP conjugated Liraglutide is pipetted in the wells. The unbound Liraglutide will compete with HRP conjugated Liraglutide to bind to the immobilized Anti-GLP1. The bound Nab-Liraglutide complex will not bind to the immobilized TNFalpha. After washing, the substrate solution (TMB) is added to the microwells. Post incubation, color develops proportionate to the amount of bound Liraglutide. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!